BRIDGE FUNDING AGREEMENT Made and signed as of the 23rd day of October, 2013Bridge Funding Agreement • September 23rd, 2014 • Cell Source, Inc. • Pharmaceutical preparations
The Investor as defined as "the Investor" in the Investment Agreement dated October 2nd, 2011, represented by Mr. David Zolty, having offices at 2727 Victoria Park Ave. Toronto, ON MlT lA6, Canada (Hereinafter: “The Investor”)
BRIDGE FUNDING AGREEMENTBridge Funding Agreement • July 11th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • New York
This Bridge Funding Agreement (this “Agreement”) is entered into as of July 11, 2023 (the “Effective Date”), between Aceragen, Inc., a Delaware corporation with a principal place of business at 505 Eagleview Boulevard, Suite 212, Exton, PA 19341 (“Aceragen”), and NovaQuest Co-Investment Fund XV, L.P., a Delaware limited partnership, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Aceragen (and its successors in interest) and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
ARTICLE 1. DEFINITIONSBridge Funding Agreement • May 13th, 1999 • General Motors Corp • Motor vehicles & passenger car bodies • New York
